BridgeBio Oncology Therapeutics (BBOT) Times Interest Earned (2024 - 2026)

BridgeBio Oncology Therapeutics (BBOT) posted Times Interest Earned of -$2.9 for Q1 2026, down 186.03% sequentially from -$1.01 in Q4 2025.

BridgeBio Oncology Therapeutics (BBOT) Times Interest Earned (2024 - 2026) Analysis & Trends

BridgeBio Oncology Therapeutics has reported Times Interest Earned for 3 years, with the latest figure at -$2.9 in Q1 2026.

Quarterly Times Interest Earned changed N/A year-over-year to -$2.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.79 (changed N/A YoY) and the FY2025 annual result came in at -$1.67, up 6.55% from the prior year.
Times Interest Earned slipped to -$2.9 in Q1 2026 per BBOT's latest filing, from -$1.01 in the prior quarter.
Over five years, Times Interest Earned peaked at -$0.48 in Q4 2024 and troughed at -$2.9 in Q1 2026.
A 3-year average of -$1.44 and a median of -$1.19 in 2025 frame the typical range for Times Interest Earned.
The widest YoY moves for Times Interest Earned: up 109.57% in 2025, down 109.57% in 2025.
Over 3 years, Times Interest Earned stood at -$0.48 in 2024, then tumbled by 109.57% to -$1.01 in 2025, then plunged by 186.03% to -$2.9 in 2026.
According to Business Quant data, Times Interest Earned over the past three periods registered -$2.9, -$1.01, and -$1.37 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Times Interest Earned (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.84
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	24.64
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-0.19
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	8.18
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-0.01
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.61
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	2.82
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.08
10	BridgeBio Oncology Therapeutics	726.38 Mn	500.67 Mn	-	-5.67

Download Data